Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice
about
Epigenome-guided analysis of the transcriptome of plaque macrophages during atherosclerosis regression reveals activation of the Wnt signaling pathwayDefining the atherogenicity of large and small lipoproteins containing apolipoprotein B100Apo E structure determines VLDL clearance and atherosclerosis risk in mice.Adipocyte LDL receptor-related protein-1 expression modulates postprandial lipid transport and glucose homeostasis in mice.Stimulation of the in vivo production of very low density lipoproteins by apolipoprotein E is independent of the presence of the low density lipoprotein receptor.Lymphatic vessel insufficiency in hypercholesterolemic mice alters lipoprotein levels and promotes atherogenesis.High Plasma Lipid Levels Reduce Efficacy of Adenovirus-Mediated Gene TherapyAdaptor protein 2 regulates receptor-mediated endocytosis and cyst formation in Giardia lamblia.The low density lipoprotein receptor modulates the effects of hypogonadism on diet-induced obesity and related metabolic perturbations.Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice.The role of the LDL receptor in apolipoprotein B secretion.Advances in experimental dyslipidemia and atherosclerosis.Cholesterol esters (CE) derived from hepatic sterol O-acyltransferase 2 (SOAT2) are associated with more atherosclerosis than CE from intestinal SOAT2Lipoprotein size and susceptibility to atherosclerosis--insights from genetically modified mouse modelsAnimal models of cardiovascular diseasesGiardia lamblia low-density lipoprotein receptor-related protein is involved in selective lipoprotein endocytosis and parasite replication.K Domain CR9 of Low Density Lipoprotein (LDL) Receptor-related Protein 1 (LRP1) Is Critical for Aggregated LDL-induced Foam Cell Formation from Human Vascular Smooth Muscle Cells.Cholesterol accumulation in tissues of the Niemann-pick type C mouse is determined by the rate of lipoprotein-cholesterol uptake through the coated-pit pathway in each organ.Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice.Macrophages, dendritic cells, and regression of atherosclerosis.Type 2 diabetes enhances arterial uptake of choline in atherosclerotic mice: an imaging study with positron emission tomography tracer ¹⁸F-fluoromethylcholineLDLR-/-ApoB100/100 mice with insulin-like growth factor II overexpression reveal a novel form of retinopathy with photoreceptor atrophy and altered morphology of the retinaLDL particle core enrichment in cholesteryl oleate increases proteoglycan binding and promotes atherosclerosis.Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic miceEpisomal Nonviral Gene Therapy Vectors Slow Progression of Atherosclerosis in a Model of Familial Hypercholesterolemia.Absence of hyperlipidemia in LDL receptor-deficient mice having apolipoprotein B100 without the putative receptor-binding sequences.Animal models for the atherosclerosis research: a review.Prospect and progress of gene therapy in treating atherosclerosis.Investigating cholesterol metabolism and ageing using a systems biology approach.ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.LDL receptor-related protein mediates cell-surface clustering and hepatic sequestration of chylomicron remnants in LDLR-deficient mice.Saturated fat-induced changes in Sf 60-400 particle composition reduces uptake of LDL by HepG2 cells.Regulatable liver expression of the rabbit apolipoprotein B mRNA-editing enzyme catalytic polypeptide 1 (APOBEC-1) in mice lacking endogenous APOBEC-1 leads to aberrant hyperediting.Hypomorphic apolipoprotein E mice: a new model of conditional gene repair to examine apolipoprotein E-mediated metabolism.Lack of genetic linkage evidence for a trans-acting factor having a large effect on plasma lipoprotein[a] levels in African Americans.Distinct metabolic and vascular effects of dietary triglycerides and cholesterol in atherosclerotic and diabetic mouse models.The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic leOverexpression of apoC-III produces lesser hypertriglyceridemia in apoB-48-only gene-targeted mice than in apoB-100-only mice.Upregulation of hepatic LDL receptor-related protein in nephrotic syndrome: response to statin therapy.Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering.
P2860
Q27311648-4DD84E75-E01A-4237-AC43-E6AE5A79CDE9Q28590506-B56E5452-C16F-47F2-BD4A-6DBABBDB4187Q30322098-DCE32872-470C-453D-80DD-3C6C602F737EQ30480233-5E124255-6E9F-4536-AE4E-CA745BEDB79EQ33182404-F5B68651-45A9-410E-B121-B9015976DAAFQ33651381-48EDCB32-BDAD-4EDB-8FE3-AE71B360C1CDQ33670765-7957693D-136B-48BD-A586-60EEA1E5688CQ33816625-1EC53DD3-CEA4-44AF-BDE2-3B942256F4EEQ33825050-93C421D6-BC45-4FFF-9C0D-FB0C9691C3F2Q33852162-903EEEAE-7FE7-47E3-81D0-82C6E6122BD0Q33939089-FF334F76-3E1A-46A4-AB0D-FF381BC54EDCQ34368686-387EE2F6-74CB-4A8B-97A2-823E0A59E54FQ34403124-2F76C8DA-569E-4B0B-92EE-9E5562767C52Q34557497-60E8BE20-83E3-4840-BFA4-699C9D830F43Q34591282-C81FD853-51B3-4412-8737-8EAA9B3F2216Q34594058-27A23BE1-80DB-465B-BC42-572A62DE7E29Q35721623-739F045A-05EE-4976-AA6B-F6B5376180AAQ35729504-9796F2D2-CB56-4010-8FE3-A13B7D4BCFB3Q36130584-99F8B08C-B42B-49C2-B2E3-BC8F863A1272Q36193752-C7365369-42DD-476B-8C70-5DB9D0C4FA29Q36553346-98DE3EF3-92A3-4ABB-AB4A-A9CC0DBBFA03Q37071378-D43A2857-DF11-4A64-A396-F81B2B989A86Q37076513-9267941D-E3C1-435F-9282-46EDFDFB0E46Q37202057-EBED54BF-A5A2-430B-A4A5-FD1872973E0DQ37501577-FAC3B215-00A5-42C4-8983-40062F85DD3CQ37608495-5D1FB190-CAB0-4B09-94AB-BE80FF4FC1E5Q37862141-BFD236E2-97FF-46CF-A78E-04C1C9FC2C28Q38578275-21C14B6C-EC64-43B9-90A4-31DB903CDC16Q38996605-E90B4208-0320-4EE9-97C8-A7D7B4769D72Q39614082-EAE1318C-6A7F-4577-AC01-BCB3506542C9Q39946719-336EF5EB-B0ED-46B7-B548-41F3B92E10D5Q40352934-AF6EB525-15D6-4180-91A9-1E4BD60D9AB7Q43002584-2B4CFC49-F878-43A3-B868-CC6FE0C7D14EQ43855742-6D9517CE-19F4-4BB5-9839-9B1644CE27DEQ44429366-4800414C-6A3F-40AA-B76A-4F3DBC9B26ADQ44463693-0972E99E-4E95-461B-946C-6F9A56F86178Q44881213-3249B846-71E1-4BF5-ACF8-4721982BD946Q45041090-F0BEE581-0590-40CE-8488-2FDFC918654AQ45178414-B391C707-2809-4878-8F8D-05873D55350BQ47377607-86C4175E-2365-46ED-8B7C-C3DD6268119C
P2860
Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice
description
1998 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1998
@ast
im Oktober 1998 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1998/10/15)
@sk
vědecký článek publikovaný v roce 1998
@cs
wetenschappelijk artikel (gepubliceerd op 1998/10/15)
@nl
наукова стаття, опублікована в жовтні 1998
@uk
مقالة علمية (نشرت في 15-10-1998)
@ar
name
Lipoprotein clearance mechanis ...... only" and "Apo-B100-only" mice
@ast
Lipoprotein clearance mechanis ...... only" and "Apo-B100-only" mice
@en
Lipoprotein clearance mechanis ...... only" and "Apo-B100-only" mice
@nl
type
label
Lipoprotein clearance mechanis ...... only" and "Apo-B100-only" mice
@ast
Lipoprotein clearance mechanis ...... only" and "Apo-B100-only" mice
@en
Lipoprotein clearance mechanis ...... only" and "Apo-B100-only" mice
@nl
prefLabel
Lipoprotein clearance mechanis ...... only" and "Apo-B100-only" mice
@ast
Lipoprotein clearance mechanis ...... only" and "Apo-B100-only" mice
@en
Lipoprotein clearance mechanis ...... only" and "Apo-B100-only" mice
@nl
P2093
P2860
P921
P356
P1476
Lipoprotein clearance mechanis ...... only" and "Apo-B100-only" mice
@en
P2093
C. H. Zlot
M. M. Véniant
R. Driscoll
R. L. Walzem
S. G. Young
V. Pierotti
P2860
P304
P356
10.1172/JCI4164
P407
P577
1998-10-15T00:00:00Z